Mounjaro NHS Criteria (October 2026): Who Qualifies?

01 · The core answer

Who qualifies for Mounjaro on the NHS?

Adults who meet the NICE criteria and fall into a group your local service is currently treating qualify. Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶

That means two tests apply. First, you must meet the clinical threshold. Second, your GP practice or local service must have reached your priority group. Many people pass the first test and are still waiting on the second. Our week-by-week NHS timeline guide explains how the phases are expected to unfold.

02 · Your next step

What should you do next?

Ask your GP whether your practice is treating your priority group yet, and have your BMI and any weight-related conditions to hand. If you are told to wait, you can compare the private route in our weight loss clinic overview. The Mounjaro pen starts with the 2.5mg strength at a standard price of £169.99, and a new customer's first 2.5mg pen costs £129.99 with code FIRST40.

03 · Ethnic background and BMI

Do BMI thresholds change for ethnic background?

Yes, the threshold is usually lower for some groups. People from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds are at higher risk of weight- related health problems at a lower BMI, so clinical thresholds are usually reduced by 2.5 kg/m² for these groups.

If this applies to you, mention it to your GP when you ask about NHS access. Our guide to GLP-1 eligibility criteria covers how this adjustment fits with other medicines in the same class.

04 · What disqualifies you

What disqualifies you from Mounjaro?

Some conditions rule Mounjaro out or call for extra caution, on the NHS and privately alike. You should not take it if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive. Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems.¹

Thyroid history also matters. In rodent studies tirzepatide caused thyroid C-cell tumours; it is not known whether this applies to humans, and no increase has been shown in human trials. As a precaution, tell your prescriber if you or a close relative have had medullary thyroid cancer or the inherited condition MEN 2.¹ Always share your full medical history and medicine list. If you are pregnant, stop the medicine and tell your prescriber promptly. Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive.

05 · NHS versus licence

Why are NHS criteria stricter than the licence?

The licence describes who the medicine may be given to; NHS criteria describe who the health service funds first. Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.¹¹¹

So an adult with a BMI of 32 and high blood pressure may be within the licence yet outside the current NHS priority groups. Our explainer on general Mounjaro criteria covers the licensed picture, and NHS eligibility has more on funding.

06 · Expected results

What results can treatment bring?

Results depend on dose, adherence and lifestyle, and trial averages do not predict your own result. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.

07 · Local NHS variation

Does access differ by area?

Yes, the pace of rollout is set locally, so two neighbouring areas can be at different stages. Read about how this plays out in NHS Fife and NHS Tayside. For a broader overview, our UK NHS criteria guide and the page on prescription weight loss drug criteria are good next reads.